Detailed and consistent clinical and immunological monitoring of patients with Rheumatoid Arthritis who are treated with biological agents.
Completed
- Conditions
- rheumarheumatoid arthritis10023213
- Registration Number
- NL-OMON39129
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 880
Inclusion Criteria
Rheumatoid Arthritis according to ACR criteria (criteria van American College of Rheumatology) who start with biological treatment
Age >18 years
Exclusion Criteria
Patients who understand the Dutch language insufficiently to appreciate the informed consent and to complete the Dutch questionnaires.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>(short-term) Eular response to a specific biological agent </p><br>
- Secondary Outcome Measures
Name Time Method <p>Side effects<br /><br>Long-term outcome based on radiographic joint damage<br /><br>Quality of life<br /><br>Effectiveness and cost-effectiveness of use of the developed prediction rule<br /><br>Fatigue and depressed mood<br /><br>Differences in response to therapy with biologicals between RA patients with a<br /><br>Cold or Heat type of symptom profile.</p><br>